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Objectives: To examine the characteristics of existing maternal tetanus immunization programmes for
pregnant women in low- and middle-income countries (LMICs) and to identify and understand the chal-
lenges, barriers and facilitators associated with maternal vaccine service delivery that may impact the
introduction and implementation of new maternal vaccines in the future.
Design: A mixed methods, cross sectional study with four data collection phases including a desk review,
online survey, telephone and face-to-face interviews and in country visits.
Setting: LMICs.
Results: The majority of countries (84/95; 88%) had a maternal tetanus immunization policy. Countries
with high protection at birth (PAB) were more likely to report tetanus toxoid-containing vaccine
(TTCV) coverage targets > 90%. Less than half the countries included in this study had a TTCV cover-
age target of > 90%. Procurement and distribution of TTCV was nearly always the responsibility of the
Expanded Programme on Immunization (EPI), however planning and management of maternal immu-
nization was often shared between EPI and Maternal, Newborn and Child Health (MNCH) pro-
grammes. Receipt of TTCV at the same time as the antenatal care visit correlated with high PAB.
Most countries (81/95; 85%) had an immunization safety surveillance system in place although only
11% could differentiate an adverse event following immunization (AEFI) in pregnant and non-pregnant
women.
Conclusions: Recommendations arising from the MIACSA project to strengthen existing services
currently delivering maternal tetanus immunization in LMICs include establishing and maintaining
vaccination targets, clearly defining responsibilities and fostering collaborations between EPI and
MNCH, investing in strengthening the health workforce, improving the design and use of existing
record keeping for immunization, adjusting current AEFI reporting to differentiate pregnantralia.
M.L. Giles et al. / Vaccine 38 (2020) 5268–5277 5269women and endeavoring to integrate the provision of TTCV within ANC services where
appropriate.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Background sonal influenza vaccination in countries considering the initiationMaternal immunization has emerged as a strategy to reduce the
morbidity and mortality of pregnant women and their very young
infants during the vulnerable first weeks of the infant’s life via
transfer of maternally-derived pathogen specific antibodies via
the placenta and breast milk [1–3]. Infectious diseases, particularly
pneumonia and sepsis, are leading causes of death in children
under five years of age in low- and middle-income countries
(LMIC) [4]. Whilst significant progress has been made in recent
decades to reduce mortality in children less than five years of
age, there has been less progress in reducing neonatal mortality.
In 2017, the global mortality rate for children under five years of
age was 39 per 1,000 live births, half the worldwide rate in 1990
[5]. Deaths in the first month of life were estimated in 2017 to
be 18 per 1,000 live births, down from 31 per 1,000 live births in
2000 [5]. The Sustainable Development Goals (SDGs), launched in
2015, [6] set the target 3.2 to end preventable deaths of newborns
and children under five years of age by 2030 and to reduce neona-
tal mortality to a maximum of 12 per 1,000 live births [7]. The
most common preventable deaths include preterm birth complica-
tions, birth asphyxia, acute respiratory infections and diarrhoea
[4]. Ending preventable deaths can be achieved by providing
immediate and exclusive breastfeeding, access to skilled health
professionals for antenatal, birth and post natal care, improved
access to water and sanitation and by providing immunizations.
Whilst great progress has been made globally, mortality rates in
Sub-Saharan Africa and South Asia remain substantial. As a result,
numerous countries from these regions risk being among the 60
countries projected to miss the SDGs in 2030 [8].
Vaccination against infectious diseases provided by the
Expanded Programme on Immunization (EPI) has played a key role
in improving child health. However, many childhood vaccination
schedules start at six weeks of age, and many diseases require
more than one dose of vaccine to confer adequate protection. As
a result, newborns are particularly vulnerable in the time period
prior to at least the second dose of vaccine. Young infants are par-
ticularly vulnerable to bacterial and viral infections, with mortality
highest in the first weeks of life, due to their weak innate immune
function [9]. Furthermore vaccines are in development that would
protect infants from disease that they may not respond to (respira-
tory syncytial virus vaccine), and for pathogens with intrapartum
transmission (group B streptococcus).
In 1988, the World Health Organization (WHO) estimated that
787,000 newborns worldwide died of tetanus [10]. In response,
the WHO called for maternal and neonatal tetanus elimination
(MNTE), which is defined as fewer than one neonatal tetanus case
per 1,000 live births in all districts per year. Key components of this
initiative include routine immunization of pregnant women and
women of reproductive age with tetanus toxoid containing vaccine
(TTCV), hygienic delivery and cord care practices and strengthen-
ing neonatal tetanus surveillance. [10]. The WHO estimated that
in 2015, approximately 34,000 newborns died from neonatal teta-
nus, a 96% reduction from the situation in 1988 [10]. However, as
of August 2019, 12 countries have still not attained MNTE status,
evoking the need to understand what vaccine implementation
efforts in pregnant women are required to resolve underlying bot-
tle necks [11,12].
In 2012, global recommendations on influenza vaccination sta-
ted that pregnant women should have the highest priority for sea-or expansion of influenza immunization programs [13]. Despite
these recommendations, the introduction of maternal influenza
immunization in many LMICs is lagging behind. With new mater-
nal vaccine candidates such as those targeting respiratory syncytial
virus (RSV) and group B streptococcus (GBS) in development, there
is an urgent need to identify and understand the operational dri-
vers and challenges that may support or hamper high vaccination
coverage of new vaccines in pregnant women.
WHO/UNICEF Estimates of National Immunization Coverage
(WUENIC) provide annual estimates of immunization coverage of
vaccine-preventable diseases (VPDs), including TTCV immuniza-
tion coverage of pregnant women [14]. TTCV coverage can be
assessed using TT2+ (at least two TTCV doses) and protection at
birth (PAB) data [15]. PAB is a supplemental method of determin-
ing coverage protection (especially where TT2 + is unreliable). To
monitor PAB during diphtheria, tetanus, pertussis vaccine first
(DTP1) visit, health workers record whether infants were protected
at birth by the mother’s TTCV status.
The WHO, supported by the Bill & Melinda Gates Foundation,
implemented theMaternal Immunization and Antenatal Care Situa-
tional Analysis (MIACSA) project, which started in 2016. The project
set out to identify and understand the challenges from, barriers to,
and facilitators of existing maternal tetanus immunization services
in LMICs as a learning agenda to optimise the pathway for new
maternal vaccines. This project aimed to determine how existing
health services currently deliver TTCV (and other vaccines) to preg-
nant women and the attributes associated with effective maternal
vaccine service delivery in LMICs. An important goal was to identify
what aspects need to be strengthened and what gaps need to be
addressed to facilitate the introductionof additional andnewmater-
nal vaccines such as influenza, GBS and RSV.2. Methods
2.1. Study design and data collection
An abridged methodology is described below. For a detailed
overview of the project methodology please refer to the study pro-
tocol previously published [16].
In summary, between November 2016 and September 2018, a
multi-method cross-sectional study was carried out with four
phases detailed below Fig. 1.1. Phase I – Published and unpublished data of pre-defined
maternal and child health
Published and unpublished data of pre-defined maternal and
child health indicators and World Bank Data for economic level
in 137 LMICs were reviewed. The classification for the year 2016
was used.
The following databases were used to extract data: Demo-
graphic and Health Surveys (DHS)/Multiple Indicator Cluster Sur-
veys (MICS); WUENIC; MNTEdatabase; WHO Maternal, Newborn,
Child, and Adolescent Health (MNCAH) policy surveys; World Bank
Classification; United Nations (UN) Inter-agency Group for Child
Mortality Estimation; trends in maternal mortality: 1990 to
2015, and United Nations, Department of Economic and Social
Affairs, Population Division.
Fig. 1. Countries participating in the different study phases.
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An 18 item online survey was developed to collect data on
maternal tetanus immunization service delivery models, pro-
gramme funding, type of disease surveillance, vaccine safety
surveillance and maternal vaccines other than TTCV. Non-
responders were followed up by telephone and/or email as
described in the study protocol [16]. Revisions following queries
on missing, erroneous and inconsistent data were carried out
through country visits. Service delivery models of interest for
maternal tetanus immunization were those within EPI pro-
grammes, those within Maternal Newborn Child Health (MNCH)
programmes or service delivery models that included a combina-
tion of EPI and MNCH. The survey was not sent to the WHO Euro-
pean region because the MNTE initiative is not a priority there.
Following the online survey, countries for Phase III and Phase IV
were selected based on performance of maternal immunization as
assessed by coverage of TTCV and ANC, geographic representation
and recommendations from WHO Regional Offices. The countries
were stratified into four groups; high and low maternal tetanus
vaccination performance measured as protection at birth (PAB),
with a cut-off
of 90%, and high and low ANC performance (with a cut-off of the
median ANC4 + coverage in countries with available data). The
final country selection was intended to ensure representation from
all WHO regions, including high-performing countries, MNTE pri-
ority countries (those that had not yet achieved elimination status)
and countries with high ANC4 + coverage. If a country was selected
and agreed to an ‘in-country’ visit (see below), and the survey for
Phase III was not completed prior to the visit, then the survey
was administered in-person at the time of the country visit. Selec-
tion of countries was not random and health care facilities chosen
during ‘in country’ visits were determined by the Ministry of
Health of that country.3. Phase III - telephone and face-to-face interviews for 26 LMICs
A 91-item survey with more detailed questions on the domains
included in the online survey was developed by the MIACSA Expert
Advisory Panel. The questionnaire was first pilot tested in twocountries, and adapted based on the comments provided. In-
depth telephone and in-person interviews were conducted with
EPI and MNCH programme officers in a selection of countries
[16]. Twenty-six countries participated in the telephone survey,
namely Benin, Bhutan, Botswana, Cameroon, Democratic Republic
of the Congo (DRC), Republic of Congo, Colombia, Costa Rica,
Dominica, Egypt, Ethiopia, Fiji, Gabon, Malawi, Morocco, Nicara-
gua, Niger, Pakistan, Papua New Guinea, Senegal, Sierra Leone,
South Sudan, Sri Lanka, Thailand, Tanzania and Uganda.
4. Phase IV-In-country visits for 10 LMICs
In-country visits were conducted in ten selected countries.
Week-long, in-country visits took place in Benin, Bhutan, Ethiopia,
Fiji, Gabon, Morocco, Panama, Senegal, Tanzania and Thailand.
Data collected included in-depth key informant interviews, focus
group discussions, and observations of clinical practice and review
of available documents at health care facilities.
5. Statistical analysis
All data were imported into Stata (release 15, StataCorp LCC,
Texas) for analyses. Data were checked for completeness and con-
sistency. Variables collected using a multiple-answer option were
split into individual variables reflecting each answer category.
PAB was used as dichotomous variable: low: PAB < 90% vs. high:
PAB>=90%. ANC performance was defined as the proportion of
pregnant women who attended one ANC visit during their last
pregnancy (ANC1) and the proportion of pregnant women who
attended four or more ANC visits during their last pregnancy
(ANC4 + ). To measure EPI performance, data from the desk review
(phase I described above) on coverage of the third dose of the DTP
vaccine (DTP3) and the third dose of the pentavalent vaccine (Pen-
ta3) was used as a proxy.
Summary measures (proportions, means, medians and standard
errors) were calculated for all variables using univariate analysis.
To identify maternal tetanus immunization service delivery mod-
els and process components favourable to the vaccination of preg-
nant women, associations of different service delivery process
components with PAB coverage and with country groups were
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Fig. 2. Countries with maternal tetanus immunization targets of 90% and over. Data
from online survey (n = 88) P - v a l u e s * : < 0 . 05; **: < 0 . 01 ; Group 1: very limited
potential (VLimP); Group 2: limited potential (LimP); Group 3: moderate potential
(ModP); Group 4: high potential (HighP); PAB: protection at birth.
M.L. Giles et al. / Vaccine 38 (2020) 5268–5277 5271established. Bivariate analyses were conducted to assess the rela-
tionship between different variables according to specific hypothe-
ses. The significance of the relationship was tested with Fisher’s
exact test. A two- sided P-value of 0.05 or below was considered
as significant throughout.
Generalized estimating equations (GEE) models were used to
calculate p-values for group-differences at the health facility level,
taking into account the correlation structure of the sample of 96
health facilities in 10 countries.
Countries were grouped (1) according to high and low PAB cov-
erage, and (2) according to a latent variable estimating the capacity
of the health system as regards the protection from vaccine pre-
ventable diseases. To create this latent variable latent class analysis
(LCA) was used. LCA enables the characterization of an unobserved
(latent) variable through analysis of the structure of the relation-
ship among several observed variables [17]. LCA therefore allowed
multiple indicators to simultaneously contribute to the definition
of a categorical latent variable, here by including several MNCH
and EPI performance indicators into the LCA model. The countries
were then assigned to the category with the highest probability
according to the model. The variables included in the LCA model
were PAB, TT2+, DPT3, ANC1, ANC4+, neonatal mortality rate and
maternal mortality ratio. The LCA generated four country groups
and a hypothesized gradient in the level of protection provided
against vaccine preventable diseases (VPDs) to mothers and infants
was confirmed for MNTE status. The four groups are defined as:
Group 1: Currently very limited potential (VLimP) to protect
mothers and their infants from VPDs (limited ANC and EPI
performance)
Group 2: Limited potential (LimP) to protect mothers and their
infants from VPDs (moderate ANC and EPI performance)
Group 3:Moderate potential (ModP) to protect of mothers and
their infants from VPDs (mostly successful ANC and EPI
performance)
Group 4: High potential (HighP) for protection of mothers and
their infants from VPDs (successful ANC and EPI performance)
6. Results
The global online survey was answered by 97/116 (84%) coun-
tries, of which two provided incomplete responses. These were
excluded from the analysis. Twenty-six countries completed Phase
III (telephone and/or face-to-face interviews). In each of the coun-
try visits, between 6 and 14 health facilities selected by the Min-
istry of Health, were visited leading to a total of 96 health facility
visits and health facility programme officer interviews across
countries.
6.1. Maternal tetanus immunization policy and targets
From the 95 countries responding to the online questionnaire,
84/95 (88%) reported having a written national policy on vaccinat-
ing pregnant women against tetanus. Four countries reported that
related guidelines were included in another health policy (Equato-
rial Guinea, Mali, Nepal and Togo). Overall, 88/95 (93%) of the
countries had either a policy or guideline for maternal
immunization.
Information about maternal tetanus immunization targets was
available from the online survey, where 95 countries reported their
national targets, and the frequency of reporting. Of the 88 coun-
tries with a policy or guideline, 39 (44%) had a target > 90%. Seven
countries (8%) did not indicate what the national target was, or
indicated a target < 25%. To document whether targets were set
based on the current national coverage rates, or based on ideal
rates, the targets were compared between countries with highand low PAB coverage. Countries with high PAB coverage signifi-
cantly more often reported targets of at least 90% (P-value
0.002). Group 4 countries (HighP) were also more likely to have
targets of at least 90% (P-value 0.001), whereas Group 2 countries
(LimP) were less likely to have these targets (P-value 0.023). On the
frequency of reporting, countries mostly reported coverage annu-
ally (49%), while 17% reported monthly (Fig. 2).
The country visits demonstrated that national maternal tetanus
immunization targets were not necessarily available or known at
the health facility level. During the health facility visits, 80/96
(83%) health facility managers reported having maternal tetanus
immunization targets for their health facility. At 14 heath facility
visits, staff were unaware of national targets. These 14 facilities
were located across six countries.6.2. Service delivery models for maternal tetanus immunization
To compare different service delivery strategies used in coun-
tries, the organization of service delivery process components
was examined, including procurement, programme planning and
management, vaccine distribution, training and supervision and
vaccine administration to pregnant women. In nearly all countries,
EPI was responsible for procurement (88/95; 93%) and distribution
(86/95; 91%) of TTCV. For planning and management responsibili-
ties, this was often shared between EPI and ANC (39/95 52%) and in
49/95 (52%) countries planning and management was the respon-
sibility of EPI only. (Table 1). No strategy emerged as superior with
regard to maternal tetanus immunization performance as mea-
sured by PAB.
Respondents were asked to indicate the estimated proportion of
routine maternal TTCV administered at each service delivery type,
such as facility-based ANC, facility-based EPI/immunization clinic,
outreach services or integrated campaigns. Therefore, more than
one answer could apply. Countries were found to use a mix of ser-
vices to administer maternal TTCV, which were often dependent on
the local setting, with 77% administered in ANC clinics, followed by
66% in EPI clinics (Fig. 3). The countries that reported outreach to
be the most common setting for maternal tetanus immunization
included Bangladesh, Lao People’s Democratic Republic, Myanmar,
and Sudan.
More group 1 (VLimP) countries vaccinated the majority (>50%)
of pregnant women at EPI/immunization services in health facili-
ties, compared to other countries (P-value 0.029). Group 2 (LimP)
countries were less likely to vaccinate pregnant women in EPI clin-
ics (P-value 0.019) but more often reported vaccinating pregnant
women primarily through outreach activities compared to the
Table 1
Maternal tetanus immunization service delivery responsibilities at the national level.
Procurement Planning and management Distribution Training and supervision
Expanded Programme on Immunization (EPI) only 88 49 86 69
Antenatal care (ANC) only 0 6 0 3
EPI + ANC 2 39 5 23
Other* 5 – 2 –
Unsure – 1 2 –
* Includes other government entities or international non-governmental organizations
0.0% 20.0% 40.0% 60.0% 80.0% 100.0%
Campaigns (integrated and ad hoc)
Outreach services
Immunizaon program, stac
services
Antenatal care, stac services
Percent of countries
Fig. 3. Service types offering routine maternal tetanus immunization. Data from online survey among 95 countries (five missing answers).
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often reported vaccinating over 90% of pregnant women at
facility-based ANC services compared to the other countries
(P-value 0.047).
Associations were observed between organization at the
national level and services more likely to deliver TTCV to pregnant
women. From the online survey, in 22/29 (76%) countries where
EPI services provided maternal tetanus immunization to > 50% of
all pregnant women, the EPI was responsible for planning, manage-
ment, training and supervision. Countries providing vaccinations
through ANC services to > 50% of the women more often shared
management responsibilities between EPI and MNCH programmes
(29/43, 65%).
The proportion of women receiving TTCV at the same time as
their ANC appointment was lowest in Group 1 countries and high-
est in Group 4 countries. When > 75% of women received TTCV and
ANC in a single visit, PAB > 90% was more likely (P–value 0.032).
This association remained unchanged when controlling for country
income level. A one-stop approach was less common in Group 1
countries (P-value 0.001). However not all better-performing coun-
tries used a one-stop approach. In four of the Group 4 countries,
<25% of pregnant women received the TTCV at the same time they
received ANC.6.3. Human resources
The level of skilled staff trained to vaccinate pregnant women in
ANC services was explored in the 26 telephone interviews. In most
countries, registered nurses were the most frequent skilled staff
vaccinating, followed by enrolled or auxiliary nurses. The propor-
tion of countries reporting medical doctors providing vaccines
increased at tertiary level facilities, with clinical officers most often
listed at the secondary level and registered nurses at the primary
level. Capacity to provide maternal tetanus immunization services
(including adequate space, cold chain, vaccine supply, skilled staff)
at facilities currently delivering ANC was not found to differ
between countries with low and high PAB coverage.During the 10 country visits, health facility managers were
asked about skilled staff administering maternal vaccines at their
facility. Of the 96 health facility interviews 76/96 (79%) were at pri-
mary level where vaccines were most often provided by registered
nurses or midwives. The remaining 20/96 (21%) were at secondary
or tertiary level facilities. In Group 4 (HighP) countries more regis-
tered nurses or midwives provided vaccination to pregnant women
(P value 0.032) compared with other groups while Group 2 and
Group 3 countries more often relied on enrolled nurses or auxiliary
nurses.6.4. Record keeping
Various approaches to maintaining maternal immunization
records existed (often concomitantly) in the 95 countries that par-
ticipated in the online survey. These included personal ANC
records and/or vaccination cards held by the pregnant woman
(any home-based record: 85/92; 92%), or clinic-based records
(any clinic-based information: 83/92; 90%) (Fig. 4). Electronic
information systems existed in 40/92 (43%) countries. Of these,
34/92 (37%) were for vaccinations and 21/92 (23%). for ANC. Elec-
tronic information systems were more often reported in Group 4
(HighP) countries (P-value 0.024). In some countries, vaccination
details were simultaneously registered in several places, within
multiple, coexisting documentation formats.
Information from EPI and MNCH country programme officers
obtained from the telephone interviews further revealed that
many countries relied on maternal recall (16/26; 62%) if no written
documentation on immunization details was available. Group 1
(VLimP) countries relied on maternal recall more often than other
groups (P-value 0.014), and Group 4 (HighP) less as compared to
other countries (P-value 0.046).
During the country visits, 73% of health facility managers con-
firmed that, in principle, records could be linked between the
mother and the child. Modalities included combined mother–child
health or vaccination booklets, mother-held vaccination cards, or
linked ANC and child registries. In practice, however, there were
61
74
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50
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34
43
0 10 20 30 40 50 60 70 80
Personal vaccination record (home based record)
Personal ANC record incl. vaccination (home…
ANC clinic based vaccination record (kept at clinic)
Clinic based vaccination record (kept at clinic only)
Vaccination included in ANC electronic database
Electronic database for vaccinations
Registers
Fig. 4. Countries with personal-held record keeping of past immunization. Online survey in 95 countries (two missing answers).
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of immunization details.
6.5. Immunization safety surveillance
The majority, 81/95 (85%), of countries which participated in
the online survey had established an immunization safety surveil-
lance system, which allows the identification of adverse events fol-
lowing immunization (AEFI).
During the country visits, such a safety surveillance system was
available in 70/90 health facilities (78%, six missing responses). Of
the 70 facilities reporting an AEFI system, only 11% distinguished
between pregnant and non-pregnant women. The proportion was
slightly (and significantly) higher in the high performing countries,
but still remained below 20%.
6.6. Delivery of vaccine and cold-chain
In the telephone interviews with country programme EPI and
MNCH officers, respondents were asked how they perceived the
quality of the transportation and storage conditions of vaccines
in their country at national, regional and health facility level. There
were no differences in the perceived quality of transport and stor-
age of vaccines between the country groups, and satisfaction with
the processes did not differ between countries with high and low
PAB coverage. Countries with high PAB coverage more often stated
that they were very satisfied with the process of transporting vac-
cines from health care institutions to vaccination centers, as com-
pared to countries with low PAB, which reported to be satisfied,
but to a lesser degree (data not shown).
The capacity of the storage system was further explored during
the country visits to 96 health facilities (Table 2). Only four health
facilities from two countries had concerns with their on-site cold
chain capacity or with vaccine supply. These problems were
reported in Group 2 countries only (LimP) (P-value 0.046) who
were also more likely to report TTCV stock outs. Stock-outs of TTCV
in the past were reported in 17 health facilities across six out of ten
countries.
Differences were observed among health facilities during the 10
country visits in the management of vaccines, the administration
of vaccines, and waste-disposal (Fig. 5). Group 2 country (LimP)
health facilities were less likely to have functional vaccine carriers
(P-value 0.061) and less likely to have adequate safety disposal
boxes (P-value 0.02).
6.7. Other vaccines
From the desk review, 58/98 (59%) countries with available data
had influenza vaccine included for pregnant women in their rou-tine immunization schedule. No data on other maternal vaccines
was available for 39 LMICs from the desk review database. How-
ever, maternal influenza immunization was not offered to preg-
nant women on a routine basis in any of the 58 countries. At the
same time, responses to the MIACSA online survey indicated that
24/95 (25%) had introduced maternal influenza immunization
and 9/95 (9%) maternal pertussis immunization. Most of the coun-
tries with maternal immunizations other than TTCV were located
in Latin America. The responsibility for procurement, planning
and management of maternal vaccines other than TTCV was not
always with the same organizational entity as for the maternal
tetanus programme. When this was observed during the in-
country visits, coverage was found to be significantly higher for
maternal tetanus immunization than for the additional maternal
vaccine (influenza).7. Discussion
The findings from the MIACSA project shed light on how exist-
ing health services in countries currently deliver TTCV (and other
vaccines) to pregnant women and on attributes associated with
effective maternal vaccine service delivery in LMICs. It also reveals
bottlenecks and opportunities to optimize delivery of maternal
vaccines that may be required for the introduction of additional
maternal vaccines in the future. Successful approaches identified
in this project include target setting, integrated programme coordi-
nation between EPI and MNCH and operational approaches that
maximise a woman’s access to maternal immunization at the time
of ANC.
In terms of policy and targets for maternal immunization, the
majority of countries (>90%) had a maternal tetanus immunization
policy in place, which is to be expected given that MNTE efforts
have been ongoing for over two decades [12]. Only half of these
policies, however, include TTCV coverage targets > 90%, and these
targets are not always known at the health facility level. Along
with national recommendations, setting ambitious, but, attainable
country-specific targets is recommended by theWHO as part of the
Global Vaccine Action Plan [18], which calls on countries to meet
coverage targets in every region, country and community by
2020 [18]. The MIACSA results confirm that increased use of targets
are more frequent in group 4 (HighP) countries. Setting pre-defined
targets is not only important to measure success following imple-
mentation, but may also improve coverage by incentivising vacci-
nators to achieve the target and/or identify shortcomings leading
to further interventions to address these. Therefore, continued
awareness and reinforcement about global targets at a country
level should allow countries to better monitor, evaluate and opti-
mize their programmes.
Table 2
Cold chain capacity, interviews with 96 health facility managers in 10 countries.
Does your facility have onsite cold chain capacity for vaccine storage?
PAB < 90% PAB  90% Group 1 Group 2 Group 3 Group 4 Total
No n (%) 3 (6.38) 1 (2.4) – 4 (8.9) 0 (0) 0 (0) 4 (4.2)
Yes n (%) 44 (93.62) 41 (97.6) – 41 (91.1) 33 (1 0 0) 17 (1 0 0) 91 (95.8)
Total 47 (1 0 0) 42 (1 0 0) – 44 (1 0 0) 33 (1 0 0) 17 (1 0 0) 95 (1 0 0)
Fisher’s exact 0.62 0.046/0.009* 0.293 1
Does your facility have a sufficient supply of TTCV?
PAB < 90% PAB  90% Group 1 Group 2 Group 4 Group 3 Total
No n (%) 2 (4.35) 6 (14) – 6 (13.6) 2 (6.06) 0 (0) 8 (9)
Yes n (%) 44 (95.65) 37 (86) – 38 (86.4) 31 (93.94) 18 (1 0 0) 87 (91)
Total 46 (1 0 0) 43 (1 0 0) – 44 (1 0 0) 33 (1 0 0) 18 (1 0 0) 95 (1 0 0)
Fisher’s exact 0.149 0.139 0.710 0.345
Have you experienced any stock outs of TTCV at your facility?
PAB < 90% PAB  90% Group 1 Group 2 Group 4 Group 3 Total
No n (%) 41 (89.1) 31 (72.1) – 32 (72.7) 29 (87.88) 17 (94.44) 78 (82.1)
Yes n (%) 5 (10.9) 12 (27.9) – 12 (27.3) 4 (12.12) 1 (5.56) 17 (17.9)
Total 46 (1 0 0) 43 (1 0 0) – 44 (1 0 0) 33 (1 0 0) 18 (1 0 0) 95 (1 0 0)
Fisher’s exact 0.059/0.131* 0.033/0.133* 0.401 0.180/0.092*
Group 1: very limited potential (VLimP)
Group 2: Limited potential (LimP)
Group 3: Moderate potential (ModP)
Group 4: High potential (HighP)
* p-value from generalized estimating equations
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Observing vaccinees for adverse reacons
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Fig. 5. Vaccine storage, administration and waste disposal practices observed during health facility visits (n = 95) in ten countries.
No Group 1 countries were included in the country visits
Group 2: Limited potential (LimP)
Group 3: Moderate potential (ModP)
Group 4: High potential (HighP)
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project provides the most detailed typology of maternal tetanus
immunization service delivery strategies in LMICs to date. It found
good collaboration between EPI and MNCH at various stages of ser-
vice delivery in most, and particularly in group 4 (HighP) countries.
In nearly all countries, procurement and vaccine distribution are
managed primarily by immunization programmes, which appears
logical due to the expected economies of scale and logistical syn-
ergies arising from joint procurement and storage of vaccines.
Other areas, such as planning and managing of maternal immu-
nization programmes and staff training were more often coordi-
nated jointly by national EPI and MNCH programmes,
particularly in countries where the administration of vaccines to
pregnant women is primarily done in ANC facilities. Interestingly,
countries with very limited or limited potential (group 1 and 2)
were more likely to rely primarily on services other than ANC ser-
vices, i.e. EPI clinics or EPI outreach activities. Whether factors
affecting these strategy choices are driven by limitations of ANC
service capacity or other factors still needs to be better understood.
Integrated service delivery approaches with EPI or MNCH pro-
grammes taking the lead in areas related to their expertise appears
to add value. The MIACSA project found a correlation between high
performance (PAB > 90%) and receipt of TTCV at the same time as
the woman’s ANC visit. This association remained when country
income level was controlled for. Building on this finding and sup-
porting close collaboration between EPI and MNCH/ANC services
including enabling maternal vaccination to take place simultane-
ously with ANC visits may hold the key to identifying and address-
ing shortcomings with the expansion of maternal immunization
programmes.. However, this needs to be context specific as build-
ing vaccination into ANC may not be the best approach if ANC cov-
erage is low.
Workforce shortcomings remain a challenge to increasing
opportunities for vaccinating pregnant women. Such challenges
were observed during MIACSA country visits, in particular at
decentralized levels, as have been reported in the literature
[19]. With regards to responsibilities for administering vaccines
to pregnant women at health facility level, the small sample of
health facilities visited limits generalizable conclusions. However,
it is worth mentioning that at primary level facilities often, there
was only one health worker performing the job of ANC service
provider and maternal vaccinator. This ‘‘integration” of roles
may work well currently but may also present challenges if work-
load of any individual health worker is increased by the addition
of further maternal vaccines in the future. In addition, the
increased involvement of nurses observed in primary level health
facilities compared to doctors in secondary and tertiary facilities
is worth further exploration to understand how this distribution
of responsibility may impact on the introduction of additional
maternal immunizations. Here, establishing multi-disciplinary
health workforce teams may help to overcome shortcomings
and improve efficiency of services.
Accurate record keeping of personal immunization details
enables vaccinators to confirm the vaccination status of pregnant
women. The MIACSA project found that both home-based and
facility-based records are used in a large majority of countries. In
particular, home-based records appeared valuable to track
women’s immunization status across pregnancies and their migra-
tion across different health facilities. The challenges observed with
paper-based record keeping found during country visits were sim-
ilar to those previously described in literature, such as poor data
quality, limited timeliness of information for reporting purposes
and time intensive for staff [20]. Often, duplication of paper-
based recording was evident and electronic record keeping not in
place. Furthermore, maternal recall was relied upon over 60% of
the time to inform past maternal immunization history and healthfacility managers reported that although linkage of maternal and
child records was possible, this occurred inconsistently. A system-
atic review on the validity of vaccination cards and parental recall
to estimate vaccination coverage has reported poor concordance,
with maternal recall reported to both overestimate and underesti-
mate coverage [21]. Although the sample size of health facilities
visited is small, and not necessarily representative, these findings,
taken together, suggest that further strengthening of recording
systems is warranted.
A report by the WHO Strategic Advisory Group of Experts
(SAGE) on Immunization working group on quality and use of
immunization and surveillance data found that despite consider-
able guidance documents available globally, there was a gap in
materials identified for life course and special populations such
as pregnant women [22]. Electronic information systems have
been suggested as a way to improve data completeness, timeliness
and data integrity [23]. However, this is highly dependent on the
function and design as well as the completeness and accuracy of
data contained [24]. For maternal immunization programmes, util-
ising electronic information systems may improve data collection
and allow access to data (e.g. in case of home-based record loss)
but overall success will be dependent on the local health system
readiness. Improving data use in resource limited settings requires
identification of a well-defined problem to be addressed, infras-
tructure (e.g. reliable internet access and stable electricity), sus-
tainable financing, health worker training and feedback
mechanisms on data generated [18,25].
Along with reporting of vaccination in pregnancy, immuniza-
tion safety surveillance systems are an important component of a
maternal immunization programme, given the unique safety con-
cerns in this population [26]. Having a safety surveillance system
that is able to identify a pregnant woman as the recipient of the
vaccine may facilitate early detection of any safety concerns
among this population and/or provide data to maintain confidence
in the safety of the programme. Across the large majority of visited
countries, MIACSA found that safety-reporting forms did not differ-
entiate AEFI in pregnant and non-pregnant women. AlthoughWHO
recommendations and tools for reporting of AEFI in pregnant
women exist [27], few countries are yet to implement them fully
[28]. In addition, qualitative data from the health facility visits
undertaken in this project highlight the need for on-going educa-
tion and training of health workers given uncertainty among some
health facility managers about the nature and frequency of AEFI in
pregnant women. Recommendations arising from this project
include for LMICs to adjust their current AEFI reporting to be able
to differentiate pregnant women and to increase education of
health workers to be able to recognise and report AEFI.
The MIACSA project was primarily focused on maternal tetanus
immunization. However, some study findings relate to the use of
other vaccines targeting pregnant women. Countries that had
introduced influenza or pertussis vaccines into their maternal
immunization schedule were significantly more likely to have a
PAB coverage >=90%. This may indicate that countries with a
well-functioning maternal tetanus immunization programme are
able to expand vaccination of pregnant women to include addi-
tional vaccines. In two of the visited countries, influenza vaccine
had recently been introduced but had considerably lower coverage
rates compared to TTCV. Being limited to service delivery aspects,
MIACSA was not powered to identify factors contributing to differ-
ent coverage levels. However, it was striking that for both vaccines,
different service delivery logistics were in place. In these two coun-
tries, influenza vaccine was managed outside of services providing
TTCV to pregnant women. This meant that pregnant women had to
seek influenza vaccine from clinics at different locations. Accord-
ingly, a recommendation from the observations of the MIACSA pro-
ject to prevent low uptake in pregnant women would be to allocate
5276 M.L. Giles et al. / Vaccine 38 (2020) 5268–5277responsibility for delivering new vaccines into existing maternal
immunization services or at least to ensure robust referral systems
that minimise the risk of drop out of pregnant women between
services.
This study has several limitations. The different data sources
used in the MIACSA project meant that inconsistencies between
the different databases were observed for some quantitative and
policy-related indicators. This may have been due to the different
time-points the information was collected, inconsistent definitions
across data sources, or different sampling methodologies. Besides
different sources of data, inaccurate reporting cannot be fully
excluded despite effortsmade by the countries to validate the infor-
mation provided to the study team. Another limitation was the rel-
atively small number of countries visited, and of health facilities
visitedwithin a given country. Health facilities visitedwere not ran-
domly selected but were selected by the local Ministries of Health.
They are not therefore necessarily representative of the entire coun-
try but rather may reflect a likely higher-performing part of the
health system within a particular country. It needs to be acknowl-
edged that although Phase II through to Phase IV of theMIACSA pro-
ject provide useful insights into how maternal tetanus
immunization is currently delivered to pregnant women in LMICs,
the tencountries visitedarenot representativeof all LMICs. Thefind-
ings therefore need to be interpreted with this in mind.
A strength of the MIACSA project however was related to how
the four phases were conducted in sequence, each building on
the next. Each subsequent phase added a level of granularity to
the data collected for each of the areas of interest. In addition,
the mixed methods approach allowed for quantitative and qualita-
tive data collection along with direct observation at a healthcare
facility level during the in-country visits. This added depth and
richness in understanding and interpretation of the data which
would not have been possible if the study was limited to only
one phase or methodology. It also facilitated regional balance, rep-
resentation of different vaccine delivery models and inclusion of
multiple performance category countries.8. Conclusion
Specific recommendations arising from the MIACSA project in
relation to strengthening existing services currently delivering
maternal tetanus immunization in LMICs are as follows: ;
In each of the areas listed, countries should
 Policy: Establish and maintain vaccination targets for pregnant
women and monitor progress at regular intervals.
 Service delivery: Define clear responsibilities and ensure func-
tional collaborations between EPI and MNCH from national to
health facility level. Promote efficient care practice approaches
such as vaccination at the same time as ANC visits.
 Human resources: Invest in strengthening the health work-
force both in numbers and in capacity to safely and effectively
provide maternal immunization specifically addressing short-
ages that may be evident in the context of new vaccine intro-
duction. This may include establishing multi-disciplinary
health workforce teams, to help overcome human resource
shortages and support demand creation.
 Record keeping: Improve the design and use of existing records
to reduce the reliance on maternal recall to establish vaccina-
tion status. Consider use of electronic record approaches where
paper-based recording of vaccination poses challenges in terms
of collection, data quality and/or data analysis, but only after an
assessment of capabilities (including internet access, reliable
power supply, trained staff) and availability of sustainable
funding. Cold chain: Assess capacities of their cold chain system before
introducing a new maternal vaccine.
 Immunization safety surveillance: Adjust current AEFI report-
ing to be able to differentiate pregnant women and increase
education of health workers to be able to recognise and report
AEFI appropriately.
 Introduction of other maternal vaccines: Aim to ensure that
the service delivery of new vaccines is integrated with existing
delivery channels for TTCV, where these achieve high coverage.
Where TTCV coverage is low, the introduction of new maternal
vaccines could provide important opportunities for countries to
review and strengthen the service delivery of both TTCV and
ANC services.
While maternal tetanus immunization is operational in most
LMICs introducing additional maternal vaccines presents many
challenges. It is hoped that the findings from the MIACSA project
and the implementation of these evidence-based recommenda-
tions will contribute to the achievement of global MNTE and con-
tribute to a robust platform for the introduction of new maternal
vaccines in the future.
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